Josep Tabernero, MD, PhD

Keynote Lecture: Coping with escalating healthcare costs in 2018 and beyond

07/10/2018

Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis

BRAF mutations occur in 8% to 12% of patients with mCRC and are associated with clinically poor prognosis. E+C was approved by the FDA and EMA for patients with BRAF V600E-mutant mCRC who...

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

06/25/2023

Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS

Introduction In the Phase III RECOURSE study, patients with metastatic colorectal cancer (mCRC) refractory to standard therapies demonstrated significantly extended overall survival and ...

Eric Van Cutsem , MD, PhD;

Alberto F. Sobrero , MD;

A. Ohtsu ;

Josep Tabernero , MD, PhD;

G. Argiles ;

R. Mayer ;

L. Vidot ;

S. Vera Moreno ;

07/01/2019

Precision Medicine Development in GI Oncology: Evidence-Based Guidelines Using Liquid Biopsies in Treatment, Decision Making, Optimizing Management, and Sequencing

Pierre Laurent-Puig , MD, PhD;

Clara Montagut , MD, PhD;

Josep Tabernero , MD, PhD;

07/07/2023

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

    KEYNOTE062 (NCT02494583) was a randomized, active controlled study of first-line (1L) pembrolizumab (P) or pembrolizumab plus chemotherapy (P+C) vs chemotherapy (C) in pts...

Charles S. Fuchs ;

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

07/01/2019

How to Make MSS Tumors More Sensitive for Immunotherapy?

Josep Tabernero , MD, PhD;

07/07/2023

KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

Background KRAS G12C mutation occurs in 3-4% of colorectal cancer (CRC) and is associated with poor prognosis. KRAS is a key mediator of the RAS/MAPK signaling cascade a...

Josep Tabernero , MD, PhD;

06/28/2021

Videos

Sequencing of Encorafenib Plus Cetuximab Among Patients With BRAF-Mutant Metastatic Colorectal Cancer

08/25/2023

Josep Tabernero , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Josep Tabernero, MD, PhD presented a post hoc analysis of the BEACON trial that evaluated differences among patients with BRAF V600E-mutant metastatic colorectal cancer treated with...

At the 2023 World Congress on...

08/25/2023

Oncology

PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification

Background MET amplification (METamp) is a secondary, or co-driving, genetic change in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-...

Josep Tabernero , MD, PhD;

06/28/2021